Alteration of mevalonate pathway related enzyme expressions in pressure overload-induced cardiac hypertrophy and associated heart failure with preserved ejection fraction

Cellular Physiology and Biochemistry

Volumn 32, Issue 6, 2013, Pages 1761-1775

  Chen, Bin ^a   Zhong, Li Yun ^a   Yang, Jin Xiu ^b   Pan, Yan Yun ^a   Chen, Fei ^a   Yang, Jian ^a   Wu, Tao ^a   Hu, Shen Jiang ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Zhejiang Traditional Chinese Medical Hospital   (China)

Author keywords

Cardiac hypertrophy; Diastolic dysfunction; Mevalonate pathway; Pressure overload; Small GTP binding proteins

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; FARNESYLTRANSFERASE ALPHA; FARNESYLTRANSFERASE BETA; GERANYLGERANYLTRANSFERASE TYPE I; GERANYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN FARNESYLTRANSFERASE; UNCLASSIFIED DRUG; PROTEIN FARNESYLTRANSFERASE ALPHA; PROTEIN FARNESYLTRANSFERASE BETA; TRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA COARCTATION; ARTICLE; BODY WEIGHT; CELL METABOLISM; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; DISEASE COURSE; ECHOCARDIOGRAPHY; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; LUNG WEIGHT; MALE; MEAN ARTERIAL PRESSURE; MEVALONATE PATHWAY; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULSE PRESSURE; RAT; SHAM PROCEDURE; SYSTOLIC BLOOD PRESSURE; WESTERN BLOTTING; ABDOMINAL AORTA; BLOOD PRESSURE; DISEASE ASSOCIATION; ENZYME ACTIVITY; GENE OVEREXPRESSION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART VENTRICLE OVERLOAD; SIGNAL TRANSDUCTION;

RATTUS;

ALKYL AND ARYL TRANSFERASES; ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; FARNESYLTRANSTRANSFERASE; GERANYLTRANSTRANSFERASE; HEART FAILURE; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYPERTROPHY, LEFT VENTRICULAR; MALE; MEVALONIC ACID; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NATRIURETIC PEPTIDE, BRAIN; RAS PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RHOA GTP-BINDING PROTEIN; VENTRICULAR PRESSURE;

EID: 84890451100     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000356610     Document Type: Article

References (44)

1. Vasan RS, Levy D: Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000;101:2118-2121.
2. Senni M, Redfield MM: Heart failure with preserved systolic function. A different natural history? J Am Coll Cardiol 2001;38:1277-1282.
3. Tsutsui H, Tsuchihashi M, Takeshita A: Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. Am J Cardiol 2001;88:530-533.
4. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM: Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-259.
5. Solomon SD, Verma A, Desai A, Hassanein A, Izzo J, Oparil S, Lacourciere Y, Lee J, Seifu Y, Hilkert RJ, Rocha R, Pitt B: Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension 2010;55:241-248.
6. Warita S, Kawasaki M, Tanaka R, Ono K, Kojima T, Hirose T, Iwama M, Watanabe T, Nishigaki K, Takemura G, Noda T, Watanabe S, Minatoguchi S: Effects of pitavastatin on cardiac structure and function and on prevention of atrial fibrillation in elderly hypertensive patients: a prospective study of 2-years' follow-up. Circ J 2012;76:2755-2762.
7. Fukuta H, Sane DC, Brucks S, Little WC: Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005;112:357-363.
8. Gomez-Soto FM, Romero SP, Bernal JA, Escobar MA, Puerto JL, Andrey JL, Ruiz P, Gomez F: Mortality and morbidity of newly diagnosed heart failure treated with statins: a propensity-adjusted cohort study. Int J Cardiol 2010;140:210-218.
9. Paulus WJ, van Ballegoij JJ: Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol 2010;55:526-537.
10. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 1990;343:425-430.
11. Casey PJ: Protein lipidation in cell signaling. Science 1995;268:221-225.
12. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, Kitakaze M, Liao JK: Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001;108:1429-1437.
13. Hasegawa H, Yamamoto R, Takano H, Mizukami M, Asakawa M, Nagai T, Komuro I: 3-Hydroxy-3- methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol 2003;35:953-960.
14. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, Wen J, Takeshita A: Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002;105:868-873.
15. Sun YL, Hu SJ, Wang LH, Hu Y, Zhou JY: Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. Chest 2005;128:1812-1821.
16. Nishikimi T: Do plasma levels of brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) increase in diastolic dysfunction as well as in systolic dysfunction? Circ J 2012;76:2540-2541.
17. Szkopinska A, Plochocka D: Farnesyl diphosphate synthase; regulation of product specificity. Acta Biochim Pol 2005;52:45-55.
18. Takai Y, Sasaki T, Matozaki T: Small GTP-binding proteins. Physiol Rev 2001;81:153-208.
19. Hogg K, Swedberg K, McMurray J: Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004;43:317-327.
20. Abdellatif M, Packer SE, Michael LH, Zhang D, Charng MJ, Schneider MD: A Ras-dependent pathway regulates RNA polymerase II phosphorylation in cardiac myocytes: implications for cardiac hypertrophy. Mol Cell Biol 1998;18:6729-6736.
21. Chien KR, Hoshijima M: Unravelling Ras signals in cardiovascular disease. Nat Cell Biol 2004;6:807-808.
22. Chen KH, Guo X, Ma D, Guo Y, Li Q, Yang D, Li P, Qiu X, Wen S, Xiao RP, Tang J: Dysregulation of HSG triggers vascular proliferative disorders. Nat Cell Biol 2004;6:872-883.
23. Hunter JJ, Tanaka N, Rockman HA, Ross J Jr, Chien KR: Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem 1995;270:23173-23178.
24. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA: Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 1997;137:481-492.
25. Hunter JJ, Chien KR: Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 1999;341:1276-1283.
26. Curcio A, Torella D, Iaconetti C, Pasceri E, Sabatino J, Sorrentino S, Giampa S, Micieli M, Polimeni A, Henning BJ, Leone A, Catalucci D, Ellison GM, Condorelli G, Indolfi C: MicroRNA-1 downregulation increases connexin 43 displacement and induces ventricular tachyarrhythmias in rodent hypertrophic hearts. PLoS One 2013;8:e70158.
27. Calderone A, Abdelaziz N, Colombo F, Schreiber KL, Rindt H: A farnesyltransferase inhibitor attenuates cardiac myocyte hypertrophy and gene expression. J Mol Cell Cardiol 2000;32:1127-1140.
28. Sah VP, Hoshijima M, Chien KR, Brown JH: Rho is required for Galphaq and alpha1-adrenergic receptor signaling in cardiomyocytes. Dissociation of Ras and Rho pathways. J Biol Chem 1996;271:31185-31190.
29. Aikawa R, Komuro I, Nagai R, Yazaki Y: Rho plays an important role in angiotensin II-induced hypertrophic responses in cardiac myocytes. Mol Cell Biochem 2000;212:177-182.
30. Luo JD, Zhang WW, Zhang GP, Guan JX, Chen X: Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol 1999;26:903-908.
31. Gibbs JB, Pompliano DL, Mosser SD, Rands E, Lingham RB, Singh SB, Scolnick EM, Kohl NE, Oliff A: Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo. J Biol Chem 1993;268:7617-7620.
32. Laufs U, Marra D, Node K, Liao JK: 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 1999;274:21926-21931.
33. Brown MS, Goldstein JL: Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 1980;21:505-517.
34. Oi S, Haneda T, Osaki J, Kashiwagi Y, Nakamura Y, Kawabe J, Kikuchi K: Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol 1999;376:139-148.
35. Chen GP, Li L, Yang Y, Fu M, Yao L, Wu T, Zhang XQ, Hu SJ: Chronic inhibition of farnesyl pyrophosphate synthase improves endothelial function in spontaneously hypertensive rats. Biochem Pharmacol 2010;80:1684-1689.
36. Baker KM, Booz GW, Dostal DE: Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system. Annu Rev Physiol 1992;54:227-241.
37. Li L, Yi-Ming W, Li ZZ, Zhao L, Yu YS, Li DJ, Xia CY, Liu JG, Su DF: Local RAS and inflammatory factors are involved in cardiovascular hypertrophy in spontaneously hypertensive rats. Pharmacol Res 2008;58:196-201.
38. Ye Y, Mou Y, Bai B, Li L, Chen GP, Hu SJ: Knockdown of farnesylpyrophosphate synthase prevents angiotensin II-mediated cardiac hypertrophy. Int J Biochem Cell Biol 2010;42:2056-2064.
39. Kashiwagi Y, Haneda T, Osaki J, Miyata S, Kikuchi K: Mechanical stretch activates a pathway linked to mevalonate metabolism in cultured neonatal rat heart cells. Hypertens Res 1998;21:109-119.
40. Guo DF, Sun YL, Hamet P, Inagami T: The angiotensin II type 1 receptor and receptor-associated proteins. Cell Res 2001;11:165-180.
41. Indolfi C, Di Lorenzo E, Perrino C, Stingone AM, Curcio A, Torella D, Cittadini A, Cardone L, Coppola C, Cavuto L, Arcucci O, Sacca L, Avvedimento EV, Chiariello M: Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation 2002;106:2118-2124.
42. Han J, Jiang D-M, Du C-Q, Hu S-J: Alteration of Enzyme Expressions in Mevalonate Pathway. Circ J 2011;75:1409-1417.
43. Li L, Chen GP, Yang Y, Ye Y, Yao L, Hu SJ: Chronic inhibition of farnesyl pyrophosphate synthase attenuates cardiac hypertrophy and fibrosis in spontaneously hypertensive rats. Biochem Pharmacol 2010;79:399-406.
44. Raiteri M, Arnaboldi L, McGeady P, Gelb MH, Verri D, Tagliabue C, Quarato P, Ferraboschi P, Santaniello E, Paoletti R, Fumagalli R, Corsini A: Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation. J Pharmacol Exp Ther 1997;281:1144-1153.